Choi Min Suk, Shim Hunbo, Cho Yang Hyun
Department of Thoracic and Cardiovascular Surgery, Dongguk University Ilsan Hospital, Dongguk University School of Medicine, Goyang, Korea.
Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Int J Heart Fail. 2020 Jan 22;2(1):23-44. doi: 10.36628/ijhf.2019.0015. eCollection 2020 Jan.
Acute heart failure is a potentially life-threatening condition that can lead to cardiogenic shock, which is associated with hypotension and organ failure. Although there have been many studies on the treatment for cardiogenic shock, early mortality remains high at 40-50%. No new medicines for cardiogenic shock have been developed. Recently, there has been a gradual decline in the use of the intra-aortic balloon pump mainly due to a lack of adequate hemodynamic support. Extracorporeal membrane oxygenation and the percutaneous ventricular assist device have become more widely used in recent years. A thorough understanding of the mechanisms of such mechanical support devices and their hemodynamic effects, components of the devices, implantation technique, management, criteria for indications or contraindications of use, and clinical outcomes as well as multidisciplinary decision making may improve the outcomes in patients experiencing cardiogenic shock.
急性心力衰竭是一种潜在的危及生命的病症，可导致心源性休克，而心源性休克与低血压和器官衰竭相关。尽管针对心源性休克的治疗已开展了许多研究，但早期死亡率仍高达40%-50%。尚未研发出用于治疗心源性休克的新药。近年来，主动脉内球囊反搏的使用逐渐减少，主要原因是缺乏足够的血流动力学支持。近年来，体外膜肺氧合和经皮心室辅助装置的应用更为广泛。深入了解此类机械支持装置的机制及其血流动力学效应、装置组件、植入技术、管理、使用的适应证或禁忌证标准、临床结局以及多学科决策，可能会改善心源性休克患者的治疗效果。
